Mesothelioma
Primary Outcome Measures disease free survival or time to recurrence [ Time Frame: Through out the whole study with maximum of 2 years ] time from clearance of disease till onset of recurrence of same disease overall survival [ Time Frame: till mortality of the case or 2 years maximum ] survival of the cases till mortality Secondary Outcome Measures comorbidities [ Time Frame: Through out…
Scientists may have found an easy way to identify peritoneal mesothelioma, making it easier to detect and catch the cancer earlier. These researchers may have found a link between peritoneal mesothelioma and gastrointestinal stromal tumors. The research done in the division of surgical oncology at University of California San Diego Moores Cancer Center found a…
Italian researchers have potentially found a new biomarker for mesothelioma. The biomarker is a microRNA signature. This would allow doctors to determine if someone’s cancer is mesothelioma or another type of cancer quickly. Mesothelioma is a notoriously hard to treat cancer and early diagnosis is one of the keys to patients living a longer, higher…
Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different asbestos related diseases in 70 countries. The report was published in May by Environmental Health Perspectives, which is supported by the National Institute of Environmental…
Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug up to 28 days post…
An inhalable gene therapy could potentially be approved for use in mesothelioma patients. Researchers in Japan have created two different tumor suppressing drugs that work by targeting genetic mutations. The drugs were created for non-small cell cancer and pleural mesothelioma. They are both doing well in the laboratory. The drugs are known as SFD-p16 and…
Primary Outcome Measures Progression-free survival [ Time Frame: From date of randomisation until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ] Progression-free survival is the determined by modified RECIST (pleural disease), RECIST 1.1 (for non-pleural disease), investigator reported progression or death from any cause…
Research at Temple University is looking at four different drug compounds, all used for noncancerous conditions, for treating mesothelioma. The research is part of a drug repurposing project, which tests drugs not typically used for illnesses like cancer to see if they work on the disease. Drug repurposing has become more popular over the years.…
Researchers may have found a better, less invasive way to test for mesothelioma. Normally, a biopsy is done, which requires removing tissue to diagnose mesothelioma, but a new two-part exam might make this procedure a thing of the past. The new test utilizes cytology, which looks at cells in body fluids, and immunology, which is…
Primary Outcome Measures Modification(s) in the immune blood markers of treated subjects on treatment. [ Time Frame: Assessment: between week 4 and 6 after the first dose of the treatment ] Modification(s) in the immune blood markers including cytokines, immune cells and serum autoantibody level of treated subjects. Modification(s) in the immune blood markers of treated subjects on treatment.…
